Results 101 to 110 of about 51,607 (296)

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Journal of Clinical Oncology, 2012
PURPOSE This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics.
H. Kantarjian, X. Thomas, A. Dmoszyńska, A. Wierzbowska, G. Mazur, J. Mayer, J. Gau, W. Chou, R. Buckstein, J. Čermák, C. Kuo, A. Oriol, F. Ravandi, S. Faderl, J. Delaunay, D. Lysák, M. Minden, C. Arthur   +17 more
semanticscholar   +1 more source

Adult Acute Megakaryoblastic Leukemia in a Mantle Cell Lymphoma Post Treatment and Auto‐Transplant

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu, Bi‐Hua Du, Chien Hsiao, Hui‐Hua Hsiao   +3 more
wiley   +1 more source

Effect of NPM1 Mutation Subtype and Co‐Mutation Patterns on the Outcomes of Acute Myeloid Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Introduction NPM1 mutated AML without FLT3‐ITD is considered “favorable” per the recent ELN 2022 criteria. However, our center has been challenged with treatment‐refractory patients, prompting a search for additional prognostic factors. Methods We reviewed records of NPM1 AML patients from 2015 to 2024.
Kittika Poonsombudlert, Ratdanai Yodsuwan, Sarah Mott, Kathryn Crawford, Sarah Hornberg, Anthony N. Snow, Grerk Sutamtewagul, Margarida Magalhaes‐Silverman, Prajwal Dhakal   +8 more
wiley   +1 more source

Standard dose Cytarabine-Induced Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Report

Journal of Pharmaceutical Care
The mainstay of treatment for acute myeloid leukemia (AML), cytarabine, is known to induce encephalopathy, usually at high doses. During induction chemotherapy, a 38-year-old woman with non-M3 AML experienced encephalopathy following the administration ...
Mehrshad Ebrahimpour, Samin Ghorbani Moghadam, Mostafa Kamandi, Omid Arasteh   +3 more
doaj  

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

Blood Cancer Journal, 2018
Sterile alpha motif and histidine/aspartic acid domain containing protein 1 (SAMHD1) limits the efficacy of cytarabine (ara-C) used in AML by hydrolyzing its active metabolite ara-CTP and thus represents a promising therapeutic target.
G. Rassidakis, N. Herold, I. H. Myrberg, Nikolaos Tsesmetzis, Sean G. Rudd, J. Henter, T. Schaller, S. Ng, W. Chng, B. Yan, C. Ng, F. Ravandi, M. Andreeff, H. Kantarjian, L. Medeiros, I. Xagoraris, J. Khoury   +16 more
semanticscholar   +1 more source

Harnessing nucleotide metabolism and immunity in cancer: a tumour microenvironment perspective

The FEBS Journal, EarlyView.
This review explores how changes in nucleotide metabolism affect the tumour microenvironment and immune responses in cancer. Here, we discuss the dual role of nucleotide metabolism in promoting cancer cell growth and shaping immune suppression. We highlight how therapies targeting nucleotide pathways can enhance immunotherapy efficacy, offering new ...
Hadil Suleiman, Alexandra Emerson, Peter M. Wilson, Karl A. Mulligan, Robert D. Ladner, Melissa J. LaBonte   +5 more
wiley   +1 more source

Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine

Journal of Lipid Research, 2023
Chemotherapy-induced cachexia causes severe metabolic abnormalities independently of cancer and reduces the therapeutic efficacy of chemotherapy. The underlying mechanism of chemotherapy-induced cachexia remains unclear.
Mi-Rae Park, Hye-Jin Lee, Hye-Min Jang, Nam Hoon Kim, Jun-Seok Lee, Yong Taek Jeong, Inho Kim, Sang-Hyun Choi, Kwan Sik Seo, Dong-Hoon Kim   +9 more
doaj  

Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine [PDF]

, 1977
JS Lilleyman, JF Harrison, JA Black
openalex   +1 more source

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

Haematologica, 2018
Survival in children with relapsed/refractory acute myeloid leukemia is unsatisfactory. Treatment consists of one course of fludarabine, cytarabine and liposomal daunorubicin, followed by fludarabine and cytarabine and stem-cell transplantation.
N. K. Eijkelenburg, M. Rasche, E. Ghazaly, M. Dworzak, T. Klingebiel, C. Rossig, G. Leverger, J. Starý, E. Bont, D. Chitu, Y. Bertrand, B. Brethon, B. Strahm, I. Sluis, G. Kaspers, D. Reinhardt, M. Zwaan   +16 more
semanticscholar   +1 more source

Severe generalized primary herpes treated with cytarabine. [PDF]

, 1970
B. E. Juel‐Jensen
openalex   +1 more source